Ibogaine carries severe health risks, including life-threatening irregular heart rhythms, potential brain toxicity, and potentially fatal cardiac complications.

Overview Debates Related claims Topics Sources

Former NIMH Director Steven Hyman warned at the STAT Summit that psychiatry lacks objective biomarkers to determine which patients will benefit from psychedelic treatments.

Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.

Former NIMH Director Steven Hyman questioned whether subjective psychedelic experiences are necessary for antidepressant efficacy, noting that non-hallucinogenic compounds could allow at-home prescriptions if proven effective.

The Trump administration initiative to advance government-funded ibogaine research follows calls from veterans and experts for strict safety standards on psychedelic treatments.

President Donald Trump signed an executive order in April 2026 dedicating $50 million in federal funding toward research into the psychedelic drug ibogaine.

The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.

The Food and Drug Administration has warned that ibogaine carries severe health risks, including life-threatening irregular heart rhythms and potential brain toxicity.

Multidisciplinary Association for Psychedelic Studies co-executive director Betty Aldworth stated that solving cardiac safety challenges is the central requirement before ibogaine can responsibly reach patients.

Federal funding for ibogaine clinical trials is justified by its therapeutic potential

Public attention on ibogaine was renewed following the death of 27-year-old Presley Gerber, who had traveled to Mexico for high-dose treatment while struggling with addiction.

Due to the lack of approved medical access in the U.S., Americans are paying between $5,000 and $20,000 to travel to specialized clinics in Mexico for ibogaine treatments.

The New York Times identified at least 40 clinics and wellness centers in Mexico offering ibogaine treatments, ranging from luxury operations with medical staff to informal rustic facilities.

President Donald Trump issued an executive order in April 2026 titled "Accelerating Medical Treatments for Serious Mental Illness," which directed federal agencies to accelerate research into psychedelic medicine.

Ibogaine clinics in Mexico, such as Beond Ibogaine in Cancún and Ibogaine Clinic in Playa del Carmen, market treatments for addiction, burnout, personal growth, and performance optimization.

The National Institute on Drug Abuse is funding research on ibogaine for the potential treatment of opioid use disorder in adults.

The Food and Drug Administration previously issued finalized guidance in July 2026 titled "Psychedelic Drugs: Considerations for Clinical Investigations" to assist sponsors developing psychedelic drugs.

Ibogaine is classified as an illegal Schedule I controlled substance under United States law and is unavailable for medical use in the country.

The U.S. Food and Drug Administration announced a request for information on October 5, 2026, seeking public feedback on early-phase clinical trial designs for ibogaine drug products.

The Food and Drug Administration is seeking public input on specific ibogaine trial parameters, including a proposed starting dose not exceeding 10 mg/kg and the use of small, sequential dose-ascending groups.

The Food and Drug Administration opened a public docket seeking feedback on ibogaine trial protocol elements, including dose selection, patient eligibility, safety monitoring, and study-stopping rules, with comments closing on November 20, 2026.